This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
NANOS1 / Nanos homolog 1 · IHC design guide
Design Immunohistochemistry for NANOS1
Plan chromogenic NANOS1 IHC on paraffin sections with human-reactive antibody A07276, starting at 2.5 μg/mL (datasheet). Assess cytoplasmic and membranous staining against the tissue profile, allowing for its low consistency with RNA expression (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
NANOS1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic and membranous tissue staining (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic and membranous signal in several tissues (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across paraffin sections (standard IHC practice; not target-specific) | |
| Caveat | Staining shows low consistency with RNA expression (HPA tissue IHC) | |
| Regulation | Varies by germ-cell stage (UniProt) | |
| Isoform / epitope | No annotated isoforms; one 1–292 chain (UniProt) |
Section 1
Recommended NANOS1 IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol with published NANOS1 staining in Nile tilapia testis (PMC13412013) and dogfish gonads (PMC5932020).
| Sample | Tissue sections; selected-image fixative not specified (standard IHC workflow) |
| Fixation | Image fixative and duration unreported (datasheet A07276); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-NANOS1, 2.5 μg/mL (datasheet A07276) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | NANOS1-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic and membranous expression in several tissues. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6.0 heat retrieval (page antigen-retrieval setting); the tilapia protocol specifies microwave boiling for 10 min (PMC13412013).
Section 2
What Is the Expected NANOS1 Staining Pattern?
NANOS1 is cytoplasmic, with perinuclear enrichment reported in germ cells, and has no transmembrane segment (UniProt Q8WY41). Look for staining in spermatogonia and spermatocytes (UniProt Q8WY41), while recognizing that HPA reports cytoplasmic and membranous staining across several tissues (HPA tissue IHC). The HPA IHC result is Approved but has low consistency with RNA expression, so tissue distribution alone warrants cautious interpretation (HPA tissue IHC).
| Cytoplasmic staining in spermatogonia or spermatocytes, possibly enriched near the nucleus. | This fits the reported germ-cell distribution and perinuclear localization (UniProt Q8WY41). Assess the signal within identifiable cells and compare it with a matched control; color alone cannot establish antibody specificity (general IHC practice). |
| Strong staining confined to nuclei, with little cytoplasmic signal. | Treat this as a compartment mismatch for tissue IHC because UniProt places NANOS1 in the cytoplasm (UniProt Q8WY41). HPA reports uncertain nucleoplasmic localization in ICC-IF, so nuclear signal is a prompt to check controls and assay context, rather than proof of an artefact (HPA subcellular ICC-IF). |
| Staining appears mainly in cells outside the expected germ-cell population. | Check cell identity before calling it nonspecific: HPA reports high IHC staining in several somatic cell populations, including adrenal glandular cells and bone-marrow hematopoietic cells (HPA tissue IHC). If staining also appears in a no-primary control, investigate endogenous detection activity; otherwise, assess possible cross-reactivity with an independent specificity control (general IHC practice). |
| Diffuse color covers tissue and spaces between cells, obscuring cell boundaries. | This does not give an interpretable cytoplasmic pattern (UniProt Q8WY41; general IHC practice). Compare a no-primary control and review blocking, washing, antibody concentration, and chromogen development before assigning the signal to NANOS1 (general IHC practice). |
| No signal appears in an expected positive cell population. | First verify that the expected cells are present: UniProt places adult expression mainly in spermatogonia and also in spermatocytes, but not late postmeiotic germ cells (UniProt Q8WY41). A blank result in the intended positive cells calls for a detection and retrieval check; it does not establish absence of NANOS1 by itself (general IHC practice). |
💡Expected NANOS1 appearanceCall a result consistent when identifiable spermatogonia or spermatocytes show discernible cytoplasmic staining, with possible perinuclear enrichment (UniProt Q8WY41); intense extracellular haze or isolated nuclear color should trigger control review (general IHC practice; HPA subcellular ICC-IF: nucleoplasm uncertain).
| Cell population and tissue | UniProt emphasizes germline development and adult spermatogonia, with expression also in spermatocytes (UniProt Q8WY41). HPA records high IHC staining in multiple somatic populations and low staining in soft-tissue fibroblasts (HPA tissue IHC). Use the cells visible on the section when interpreting a result; neither profile alone proves specificity. |
| Compartment and membrane-associated staining | UniProt places NANOS1 in the cytoplasm and reports no transmembrane segment (UniProt Q8WY41). HPA describes cytoplasmic and membranous tissue staining (HPA tissue IHC). Membranous color may match that observation, but topology alone cannot confirm that a membrane outline represents specific NANOS1 staining. |
| Strength of tissue IHC evidence | The listed antibody CAB012219 has Approved IHC status, while the HPA tissue profile notes low consistency between antibody staining and RNA expression (HPA antibodies; HPA tissue IHC). Interpret unexpected cell populations with matched controls and morphology; Approved status does not resolve that reported inconsistency. |
| Processing and isoform annotation | UniProt lists a single 1–292 chain, no signal peptide or propeptide, and no annotated isoforms or glycosylation sites (UniProt Q8WY41). These annotations give no basis here for predicting a cleaved, shed, or glycosylated staining pattern; the antibody epitope is not supplied. |
| IF/ICC: should its localization set the paraffin IHC call? | HPA ICC-IF supports cytosol localization and labels nucleoplasm uncertain; images are listed for A-431, U-251MG, and U2OS (HPA subcellular ICC-IF). Use that as a compartment cross-check, while scoring this paraffin IHC section against its tissue morphology and controls (general IHC practice). |
| Antigen retrieval | Retrieval is a general variable in paraffin IHC (general IHC practice). No NANOS1-specific retrieval condition or fixation sensitivity is supplied, so optimize against a suitable positive section and its controls without attributing a weak result to a documented NANOS1 fixation effect. |
| Situation | Likely cause | Next action |
|---|---|---|
| The intended positive germ cells are blank. | The sampled area may lack spermatogonia or spermatocytes (UniProt Q8WY41), or the IHC detection workflow may have failed (general IHC practice). | Confirm cell identity on the counterstained section, then review the positive control, retrieval, primary-antibody step, and detection reagents (general IHC practice). Avoid treating late postmeiotic cells as the expected positive population (UniProt Q8WY41). |
| Color persists when the primary antibody is omitted. | Endogenous enzyme activity, endogenous biotin where a biotin-based system is used, or detection-reagent background can produce color (general IHC practice). | Identify the detection chemistry and apply its appropriate endogenous-activity block; compare the adjusted no-primary control with the test section (general IHC practice). Do not score persistent control color as NANOS1. |
| Many unrelated cells stain intensely. | Some somatic staining is reported by HPA, while its tissue IHC profile also has low consistency with RNA data (HPA tissue IHC). Excess primary antibody or cross-reactivity remains possible (general IHC practice). | Map staining to cell types and tissue compartments, compare controls, and titrate the IHC-validated antibody under the same detection conditions (general IHC practice). Seek independent specificity evidence before making a new cell-type claim. |
| The slide has widespread haze or granular deposits. | Inadequate blocking or washing, concentrated antibody, or overdevelopment can obscure a cell-bound signal (general IHC practice). | Check the no-primary control, improve blocking and washes, and adjust primary-antibody concentration or chromogen development one variable at a time (general IHC practice). Reassess whether clear cytoplasmic cell boundaries emerge. |
| Staining is exclusively nuclear. | That conflicts with UniProt's cytoplasmic assignment, although HPA calls nucleoplasmic ICC-IF localization uncertain (UniProt Q8WY41; HPA subcellular ICC-IF). | Recheck cell boundaries and counterstain, compare negative and positive controls, and verify the pattern with independent specificity evidence (general IHC practice). Do not promote uncertain ICC-IF nuclear localization to an established tissue IHC pattern. |
| The section shows a sharp membrane outline without convincing cytoplasmic color. | HPA reports membranous tissue staining, but NANOS1 has no transmembrane segment (HPA tissue IHC; UniProt Q8WY41). The outline alone cannot settle specificity. | Review adjacent cells and matched controls for a reproducible cell-associated pattern, then corroborate an isolated membrane result before scoring it as NANOS1 (general IHC practice). |
Experiment evidence
IHC & IF images showing NANOS1 staining
A07276 · IHCImmunohistochemistry of Nanos1 in human brain tissue with Nanos1 antibody at 2.5 μg/mL
A07276 · IFImmunofluorescence of nanos1 in human brain tissue with nanos1 antibody at 20 μg/mL.
A07276-1 · IFImmunofluorescence of nanos1 in human brain tissue with nanos1 antibody at 20 μg/mL.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000188613-NANOS1/tissue/cerebral+cortex#imid_3451464
HPA · StomachHuman Protein Atlas IHC, Stomach. Source: https://www.proteinatlas.org/ENSG00000188613-NANOS1/tissue/stomach+2#imid_3451356
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000188613-NANOS1/tissue/colon#imid_3451390
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000188613-NANOS1/tissue/liver#imid_3451399
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB012219; green = NANOS1, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB012219; green = NANOS1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for NANOS1 IHC & IF
🧪Run bronchus first: respiratory epithelial cells are the expected positive population (HPA: High in bronchus respiratory epithelial cells). HPA detects NANOS1 in all 45 scored tissues, so there is no HPA-supported negative tissue; use no-primary and isotype controls, and treat any unstained cells on the positive slide as a background reference rather than validated NANOS1-negative cells (HPA: no negative tissue rows).
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: None in HPA: NANOS1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show NANOS1 in A-431, U-251MG, U2OS, with annotated localisation: Nucleoplasm (uncertain), Cytosol (supported) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only section and an isotype-matched antibody control of the same host species and clonality; confirm specificity with NANOS1 knockout tissue or a peptide-block control if a suitable immunizing peptide is available (standard IHC controls). Block endogenous peroxidase for chromogenic detection, particularly when evaluating blood-derived cells in the section (standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A07276 brain IHC caption does not state a fixative (selected-SKU tissue-IHC caption: fixative not stated). Retrieval dependency is unreported; optimize antigen retrieval on matched paraffin sections, and do not assume frozen sections or IF/ICC will be easier (supplied target/application evidence: no matched comparison). Evaluate cytoplasmic staining against tissue background, while checking for endogenous peroxidase signal in blood-derived cells (UniProt Q8WY41: cytoplasmic and perinuclear localization; standard IHC practice).
HPA tissue IHC evidence for NANOS1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Low consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
| Cervix | Glandular cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: NANOS1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced NANOS1 IHC Tips
Troubleshoot NANOS1 staining in paraffin sections by checking retrieval, compartment, cell identity, and controls before interpreting chromogenic signal.
How should I retrieve NANOS1 in paraffin sections when staining is weak?
Start with citrate buffer at pH 6.0, heated to 95–98 °C for 20 min (page antigen retrieval setting). Let sections cool in the retrieval buffer, then compare staining with a section processed in the same run without primary antibody (standard IHC practice). The catalog image reports staining in human brain at 2.5 µg/mL, but its caption does not specify retrieval conditions (A07276 caption). If staining remains weak, test EDTA at pH 9.0 on adjacent sections as a fallback, keeping detection conditions identical (standard IHC practice). Judge improvement by cellular cytoplasmic signal rather than stronger staining at section edges (UniProt Q8WY41 localisation; standard IHC practice).
Could fixation explain absent or patchy NANOS1 staining?
Target-specific fixation sensitivity is unknown: the selected antibody's tissue caption does not state a fixative (A07276 caption). For paraffin IHC, record fixation conditions and compare sections processed with matched retrieval and detection steps before attributing a difference to NANOS1 (standard IHC practice). Examine intact tissue away from folds and cut edges, where processing and reagent exposure can differ (standard IHC practice). If archival blocks vary in fixation history, assess a dilution series around the caption's 2.5 µg/mL concentration on comparable sections (A07276 caption; standard IHC practice). Do not infer fixation tolerance from the reported tissue staining pattern or protein features (HPA tissue IHC; UniProt Q8WY41).
Where should convincing NANOS1 staining appear within cells?
Prioritise cytoplasmic staining, including a perinuclear pattern, when evaluating NANOS1 in chromogenic sections (UniProt Q8WY41 localisation). Cytosolic localisation is supported in cell imaging, while the reported nucleoplasmic location is uncertain (HPA subcellular). UniProt reports no transmembrane segment, so an exclusively sharp membrane rim warrants scrutiny even though tissue IHC reports membranous expression (UniProt Q8WY41 topology; HPA tissue IHC). Compare the pattern at 2 antibody concentrations and against a no-primary section to identify diffuse deposition or endogenous chromogen (standard IHC practice). Use cell morphology and the expected tissue compartment alongside stain intensity; localisation alone cannot establish antibody specificity (standard IHC practice).
How do I assess an unexpected NANOS1 staining pattern without a mapped epitope?
The supplied record lists 0 isoforms, no signal peptide or propeptide, and a single 1–292 chain (UniProt Q8WY41). It also lists 0 glycosylation sites and 0 modified residues, but gives no antibody epitope (UniProt Q8WY41; supplied antibody evidence). Do not explain a distinct compartment or staining intensity as an isoform-specific result without independent epitope information (standard IHC interpretation). Compare adjacent sections across an antibody dilution series, including the caption concentration of 2.5 µg/mL, while holding retrieval constant (A07276 caption; standard IHC practice). Resolve persistent discrepancies with an independent antibody recognising a documented different epitope, if available (standard IHC practice).
How can IF help check cell identity and compartment in NANOS1-positive sections?
Use a multiplex IF section with a marker for the expected cell population; spermatogonia are a relevant example where germline tissue is under study (UniProt Q8WY41 tissue specificity; standard IF practice). Select fluorophores after inspecting unstained tissue for autofluorescence, and favour a spectrally separated far-red channel when background is strongest at shorter wavelengths (standard IF practice). Permeabilise sufficiently to expose the cytoplasmic epitope, then compare matched permeabilised and minimally permeabilised sections because the antibody epitope is not supplied (UniProt Q8WY41 localisation; supplied antibody evidence; standard IF practice). Include single-colour and no-primary controls to check channel bleed-through and background (standard IF practice). Score colocalisation within individual cells rather than inferring it from overlapping tissue regions (standard IF practice).
What should I check when NANOS1 chromogen spreads across the section?
Run a no-primary control through the same peroxidase detection and DAB steps to locate background unrelated to primary antibody binding (standard IHC practice). Check the peroxidase block, wash steps, and blocking conditions, especially if pigment appears in many cell types or around damaged tissue (standard IHC practice). Titrate the primary antibody around the reported 2.5 µg/mL image concentration while keeping incubation time and detection constant (A07276 caption; standard IHC practice). Treat staining concentrated at edges, folds, or necrotic areas as suspect until matched intact regions show the same cellular pattern (standard IHC practice). Compare cytoplasmic signal with the expected NANOS1 localisation before calling diffuse background positive (UniProt Q8WY41 localisation).
How should I quantify NANOS1 staining across tissue regions? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and region before scoring, then report the percentage of positive cells and an H-score combining that percentage with ordinal intensity (standard IHC practice). For sparse positive cells, report positive-cell density per mm² of viable tissue as a complementary measure (standard IHC practice). Normalise comparisons to the same eligible cell type or viable area, and keep retrieval, antibody concentration, detection, and imaging settings matched (standard IHC practice). Record cytoplasmic and membrane-associated signals separately because tissue IHC reports both patterns while UniProt places NANOS1 in the cytoplasm (HPA tissue IHC; UniProt Q8WY41 localisation). Flag interpretive uncertainty: the HPA tissue entry is Approved but reports low consistency with RNA expression (HPA tissue IHC).
When is NANOS1 staining credible rather than an artefact?
A credible result shows reproducible cellular staining in intact tissue, with cytoplasmic or perinuclear signal consistent with the UniProt localisation (UniProt Q8WY41; standard IHC practice). Cell identity matters: NANOS1 is reported mainly in spermatogonia in adult germline tissue and is absent from late post-meiotic germ cells (UniProt Q8WY41 tissue specificity). Investigate exclusively nuclear staining, a sharp membrane-only rim, or signal confined to edges and necrosis before interpreting it as NANOS1 (UniProt Q8WY41 topology and localisation; standard IHC practice). A no-primary control can reveal endogenous enzyme activity or nonspecific DAB deposition (standard IHC practice). Interpret positives cautiously across tissues because the HPA entry reports low staining-to-RNA consistency (HPA tissue IHC).
Boster reagents
Best NANOS1 / Nanos homolog 1 IHC Antibodies
The catalog shows human brain IHC and IF images for anti-NANOS1 antibodies (A07276 IHC image caption; A07276-1 IF image caption). Listed reactivity includes human, mouse, and rat (catalog reactivity).
Real IHC data
Anti-Nanos homolog 1 Nanos1 Antibody
Cat # A07276
Real IF data
Anti-Nanos homolog 1 Nanos1 Antibody
Cat # A07276-1
A07276 renders with a human brain IHC image at 2.5 μg/mL and lists human IHC-P and IF (A07276 IHC image caption; A07276 applications/reactivity). A07276-1 renders with a human brain IF image at 20 μg/mL and lists IF plus human, mouse, and rat reactivity (A07276-1 IF image caption; A07276-1 applications/reactivity).
Which to pick: Choose A07276 for human paraffin-section chromogenic IHC: it lists IHC-P, and its own IHC image shows human brain tissue; the fixative is unreported (A07276 applications; A07276 IHC image caption). For IF, A07276-1 has a human brain IF image, but ICC is not listed for either SKU (A07276-1 IF image caption; catalog applications). For work involving mouse or rat, A07276-1 lists those species as reactive, though its pictured IF sample is human; both antibodies have rabbit hosts and no reported clone, so clonality cannot guide the choice (A07276-1 reactivity; A07276-1 IF image caption; catalog host/clone).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q8WY41 (NANO1_HUMAN, Nanos homolog 1).
- Human Protein Atlas. NANOS1 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. NANOS1 subcellular location (ICC-IF): Localized to the nucleoplasm and cytosol..
- Human Protein Atlas. NANOS1 antibody validation summary (1 antibodies).
- Spermatogonial stem cell markers and distribution in different regions of the testis of adult Nile tilapia (Oreochromis niloticus). Animal reproduction 2026 — PMC13412013.
- The nanos1 gene was duplicated in early Vertebrates and the two paralogs show different gonadal expression profiles in a shark. Scientific reports 2018 — PMC5932020.
- PubMed PMID:12690449 — UniProt-cited evidence.
- PubMed PMID:17047063 — UniProt-cited evidence.
- PubMed PMID:15164054 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for NANOS1 (Nanos homolog 1). Expected localisation Cytoplasmic and membranous tissue staining (HPA tissue IHC). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A07276 at 2.5 μg/mL (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Tissue sections; selected-image fixative not specified (standard IHC workflow); 2. Fixation: Image fixative and duration unreported (datasheet A07276); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-NANOS1, 2.5 μg/mL (datasheet A07276); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across paraffin sections (standard IHC practice; not target-specific); Caveat: Staining shows low consistency with RNA expression (HPA tissue IHC); Isoform / epitope: No annotated isoforms; one 1–292 chain (UniProt); Regulation: Varies by germ-cell stage (UniProt). Evidence: UniProt Q8WY41, HPA tissue IHC · Approved, HPA ICC-IF · nucleoplasm and cytosol., Datasheet A07276, PMC13412013, PMC5932020. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/NANOS1/immunohistochemistry-ihc-guide.